SAFC has coupled its chiral screening and small-scale purification services to meet what it says is a boom in demand for more complete chemical analysis from drugmakers.
The UK pharma manufacturing market is predicted to see a modest 2.7 per cent growth over the next five years largely due to pricing schemes set by the Government, according to a new report.
Milan head-quartered plant extract specialist, Indena, has been granted the ISO14001 certification for its Tours production site in France, marking the second for its five production sites.
Catalent has upgraded its North Carolina, US, sterile development and analytics plant to increase its aseptic fill-finish activities four-fold in a bid to boost its integrated biologics offering.
Schenck Accurate, Malvern, PSL and Sturtevant have teamed up to create a “unique” new turnkey isolated milling suite which they say will wipe out unnecessary waiting times for high potency (HP) drug processing.
Bend Research says the addition of a new 18mm extruder to its hot melt tech will cut costs and will allow it work with customers earlier in the drug development process.
Lonza is targeting the gene therapy sector through a new partnership with Avalanche Biotechnologies that will seek to outlicense viral vector tech and process development knowhow.
The US FDA will have more powers to inspect ‘risky’ overseas pharmaceutical plants according to supporters of a bill being considered by the US senate this week.
EMD Millipore premiered a new single-use bioreactor at Interphex 2012, claiming the new design addresses industry demand for ease of use and flexibility.
in-PharmaTechnologist.com presents the latest new facilities to spring up all over the world, including a plasma-based therapy expansion for Baxter, a North African foray for Julphar, and a supply chain step-up for Vetter.
in-Pharmatechnologist.com was at Interphex 2012 in New York, US to launch the revamped version of our website and speak to the pharmaceutical manufacturing and processing tech sector’s movers and shakers.
Continuous processing is still hamstrung by a lack of control systems and is not ready for specific FDA guidance according to an industry expert panel which met at Interphex last week.
Contract manufacturing organisations (CMOs) have been busy in the past week, with OsoBio expanding its plant and AMRI adopting a new relationship strategy.
